Fauad Hasan

Fauad Hasan has 22 years of success as a biopharma drug developer and entrepreneur. Most recently Mr. Hasan served as the co-founder and Chief Executive Officer of Bonti from its inception in 2015 until the company was acquired by Allergen (NASDAQ:AGN) in October 2018 for the upfront payment of $195M (> 6x multiple on invested capital in 3 years) and subsequent milestone payments. Additionally, Mr. Hasan has served in various leadership roles at Regeneron, Baxter (now Takeda), and Allergan (now AbbVie). Mr. Hasan contributed to the development of several multi-billion-dollar blockbuster drugs, such as Eylea®, Recombinate™, and Botox®.